Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LifeTech Scientific Corporation
先健科技公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

ANNOUNCEMENT ON NOT TO PROCEED WITH THE MAJOR TRANSACTION

Reference is made to the announcement of LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 22 May 2026 in relation to the major transaction involving the proposed acquisition of the Starway Equity and the proposed issue of Convertible Bonds under Specific Mandate, conditional upon the fulfilment of conditions precedent (the "**Announcement**"). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Announcement.

Since the publication of the Announcement, the Company has negotiated with the Seller on the definitive transaction documents for the Transaction, including the equity purchase agreement and the instrument for the Convertible Bonds, among others. However, the two parties are unable to reach a consensus as of the date of this announcement. Having conducted a prudent assessment, the Company considers that it remains unlikely that a consensus could be reached within a reasonable timeframe, and that if the current situation persists, it may result in continued uncertainty and may also adversely affect the Group's operations and even Shareholders' confidence in the Company.

With a view to eliminating such potential uncertainty and adverse effects, after prudent consideration, the Board has resolved not to proceed with the Transaction.

As the Company will not proceed with the Transaction, no circular will be despatched to the Shareholders and no EGM will be convened for the purpose of considering and approving the Transaction, the issue of the Convertible Bonds and the Specific Mandate.

As of the date of this announcement, while the Board considers that such decision not to proceed with the Transaction will not have any material adverse impact on the ordinary course of business of the Group taken as a whole, the Company will continue to monitor and assess any impact on the Group that may arise as a result thereof.

In the meantime, the Company will focus on business development, actively improve corporate governance and enhance operational efficiency, leverage the Company's brand advantage accumulated over 27 years in the field of cardiovascular medical devices, accelerate the launch of new products in both domestic and overseas markets, and further expand its international market share.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 20 July 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.